XXXX nanotubes part II: a remarkable carrier for drug and gene delivery.

@entity632 @entity1501 @entity137 @entity2379 @entity5 @entity900 @entity1311 @entity1307 @entity505 @entity1499 @entity136
INTRODUCTION: @entity505 nanotubes (CNT) have recently been studied as novel and versatile drug and gene delivery vehicles. When CNT are suitably functionalized, they can interact with various cell types and are taken up by endocytosis. Areas covered: Anti- @entity5 drugs @entity900 and @entity632 have been delivered by CNT, as well as @entity1499 , @entity1311 and @entity136 . The delivery of the antifungal compound @entity2379 and the oral administration of @entity1307 have both been assisted using CNT. Frequently, targeting moieties such as @entity1501 , epidermal growth factor or various antibodies are attached to the CNT-drug nanovehicle. Different kinds of functionalization (e.g., polycations) have been used to allow CNT to act as gene delivery vectors. Plasmid DNA, small interfering RNA and micro-RNA have all been delivered by CNT vehicles. Significant concerns are raised about the nanotoxicology of the CNT and their potentially damaging effects on the environment. Expert opinion: CNT-mediated drug delivery has been studied for over a decade, and both in vitro and in vivo studies have been reported. The future success of CNTs as vectors in vivo and in clinical application will depend on achievement of efficacious therapy with minimal adverse effects and avoidance of possible @entity137 and environmentally damaging effects.
